Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Zinc (Zn) hyper-accumulates in breast tumors and malignant cell lines compared to normal mammary epithelium. The mechanisms responsible for Zn accumulation and the consequence of Zn dysregulation are poorly understood. METHODS: Microarrays were performed to assess differences in the expression of Zn transporters and metallothioneins (MTs) in human breast tumors and breast cancer cell lines. Real-time PCR and immunoblotting were employed to profile Zn transporter expression in representative luminal (T47D), basal (MDA-MB-231), and non-malignant (MCF10A) cell lines. Zn distribution in human tumors was assessed by X-ray fluorescence imaging. Zn distribution and content in cell lines was measured using FluoZin-3 imaging, and quantification and atomic absorption spectroscopy. Functional consequences of ZnT2 over-expression in MDA-MB-231 cells including invasion, proliferation, and cell cycle were measured using Boyden chambers, MTT assays, and flow cytometry, respectively. RESULTS: Gene expression profiling of human breast tumors and breast cancer cell lines identified subtype-specific dysregulation in the Zn transporting network. X-ray fluorescence imaging of breast tumor tissues revealed Zn hyper-accumulation at the margins of Luminal breast tumors while Zn was more evenly distributed within Basal tumors. While both T47D and MDA-MB-231 cells hyper-accumulated Zn relative to MCF10A cells, T47D cells accumulated 2.5-fold more Zn compared to MDA-MB-231 cells. FluoZin-3 imaging indicated that Zn was sequestered into numerous large vesicles in T47D cells, but was retained in the cytoplasm and found in fewer and larger, amorphous sub-cellular compartments in MDA-MB-231 cells. The differences in Zn localization mirrored the relative abundance of the Zn transporter ZnT2; T47D cells over-expressed ZnT2, whereas MDA-MB-231 cells did not express ZnT2 protein due to proteasomal degradation. To determine the functional relevance of the lack of ZnT2 in MDA-MB-231cells, cells were transfected to express ZnT2. ZnT2 over-expression led to Zn vesicularization, shifts in cell cycle, enhanced apoptosis, and reduced proliferation and invasion. CONCLUSIONS: This comprehensive analysis of the Zn transporting network in malignant breast tumors and cell lines illustrates that distinct subtype-specific dysregulation of Zn management may underlie phenotypic characteristics of breast cancers such as grade, invasiveness, metastatic potential, and response to therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kao, J., Salari, K., Bocanegra, M., Choi, Y.-L., Girard, L., Gandhi, J., Kwei, K. A., Hernandez-Boussard, T., Wang, P., Gazdar, A. F., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006146 · Cited by 788 · cited 1×
“Breast cancer cell lines were classified into basal and luminal based on previously published work and the unassigned cell lines were classified based on cluster membership after Hierarchical clustering of the top 10 % highly variant genes [62, 63].”
MethodLiuzzi, J. P., Lichten, L. A., Rivera, S., Blanchard, R. K., Aydemir, T. B., Knutson, M. D., Ganz, T., & Cousins, R. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502257102 · Cited by 594 · cited 1×
“Summary of the molecular mass of Zn transporters and antibodies used for detection [68–87].”
MethodFukada, T., Civic, N., Furuichi, T., Shimoda, S., Mishima, K., Higashiyama, H., Idaira, Y., Asada, Y., Kitamura, H., Yamasaki, S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003642 · Cited by 287 · cited 1×
“Moreover, ZIP7 [37], ZIP13 [38], and ZIP14 [39] have been shown to specifically activate EGFR, TGFβ, and G-protein coupled receptor-mediated cAMPCREB signaling, respectively.”
BackgroundMammalian metallothioneins: properties and functions
Babula, P., Masarik, M., Adam, V., Eckschlager, T., Stiborova, M., Trnkova, L., Skutkova, H., Provaznik, I., Hubalek, J., & Kizek, R. (2012) · Metallomics · doi:10.1039/c2mt20081c · Cited by 255
Zinc transporter ZIP8 (SLC39A8) and zinc influence IFN-γ expression in activated human T cells
Aydemir, T. B., Liuzzi, J. P., McClellan, S., & Cousins, R. J. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.1208759 · Cited by 229
Cited by
Chen, B., Yu, P., Chan, W. N., Xie, F., Zhang, Y., Liang, L., Leung, K. T., Lo, K. W., Yu, J., Tse, G. M. K., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01679-y · Cited by 420
The emerging role of zinc transporters in cellular homeostasis and cancer
Bafaro, E., Liu, Y., Xu, Y., & Dempski, R. E. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.29 · Cited by 307
Zhou, T., Rodríguez-Barrios, S., Ruisánchez, I., & Rivera-Gil, P. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117897 · Cited by 4
Metadata
- Authors
- Chandler, P., Kochupurakkal, B. S., Alam, S., Richardson, A. L., Soybel, D. I., & Kelleher, S. L.
- Venue
- Molecular Cancer
- Published
- 2016-01-05
- Volume
- 15
- Issue
- 1
- Pages
- 2-2
- ISSN
- 1476-4598 (ISSN-L)
- OpenAlex
- W2228574729
- Cited by
- 97
- References
- 5
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer. https://app.cochat.ai/papers/10.1186/s12943-015-0486-y
- The paper
- Chandler, P., Kochupurakkal, B. S., Alam, S., Richardson, A. L., Soybel, D. I., & Kelleher, S. L. (2016). Subtype-specific accumulation of intracellular zinc pools is associated with the malignant phenotype in breast cancer. Molecular Cancer. https://doi.org/10.1186/s12943-015-0486-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.